PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
09-Dec-2022 Non-invasive Surgical Wound Closure Market to grow at a rate of 4.1% by 2022-2032 | Get Customized Reports MARKITWIRED
09-Dec-2022 Mobile Cardiac Telemetry Systems Market worth US$ 3.0 billion by 2032 at a CAGR of 12.5% | FMI MARKITWIRED
09-Dec-2022 Rise in Demand for Minimal Invasive Procedures, and Rapidly Aging Global Population are Uplifting the Arthroscopy Visualization Systems Market: Future Market Insights MARKITWIRED
09-Dec-2022 Synthetic Biology Market will reach a value of US$ 138.8 Bn by 2032 at a CAGR of 24.3% | Future Market Insights MARKITWIRED
09-Dec-2022 Point-Of-Care Breathalyzer Market demand is projected to be valued at US$ 385.7 Million in 2022 | Future Market Insights MARKITWIRED
09-Dec-2022 Rising Pediatric and Geriatric Patient Preference for Softgel Capsules is expected to Drive Market Growth: Future Market Insights MARKITWIRED
09-Dec-2022 Proteomics Market size to reach around US$ 109.4 Billion by the end of 2032 | CAGR of 13.5% | Future Market Insights MARKITWIRED
09-Dec-2022 Synthetic Biology Market will reach a value of US$ 138.8 Bn by 2032 at a CAGR of 24.3% | Future Market Insights MARKITWIRED
09-Dec-2022 Teeth Whitening Market value is estimated to reach US$ 6.6 Bn in 2022 and is expected to reach US$ 10.7 Bn by the year 2032 end – FMI MARKITWIRED
09-Dec-2022 QDENGA®▼ (vaccin tétravalent contre la dengue [vivant, atténué]) de Takeda est autorisé dans l'Union européenne Businesswire
09-Dec-2022 $4.8 Billion Worldwide Oligonucleotide Synthesis Industry to 2027: Players Include Agilent Technologies, Biolegio, Eurofins Genomics and GenScript Among Others - ResearchAndMarkets.com Businesswire
09-Dec-2022 QDENGA®▼ (tetravalenter Dengue-Impfstoff [abgeschwächter Lebendimpfstoff]) von Takeda erhält EU-Marktzulassung Businesswire
09-Dec-2022 Surface Disinfectant Global Market Report 2022: Increasing Healthcare Expenditures and An Emphasis on Them in Emerging Nations Presents an Opportunity - ResearchAndMarkets.com Businesswire
09-Dec-2022 Pistoia Alliance Expands Diversity & Inclusion Leadership Program to Offer Rare Cross-Industry Collaboration Opportunity and Encourage Industry Transformation Pistoia Alliance
09-Dec-2022 Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid▼ showing statistically significant relative risk reduction in major adverse CV events1,2 Daiichi Sankyo UK
09-Dec-2022 Weekly Pharma & Life Science News Round-Up: 5th – 9th December 2022 PharmiWeb.Jobs
09-Dec-2022 Medical Waste Management System Market is projected to reach US$ 15,354.4 Million by 2032 at a CAGR of 6.6% MARKITWIRED
09-Dec-2022 Glioblastoma Treatment Drugs Market is expected to be valued at US$ 1,259.13 million by 2032 at a CAGR of 5.7% MARKITWIRED
09-Dec-2022 Camizestrant significantly delayed disease progression in advanced ER-positive breast cancer, adding at least 3.5 months benefit versus FASLODEX® (fulvestrant) AstraZeneca
09-Dec-2022 Capivasertib plus FASLODEX® (fulvestrant) reduced the risk of disease progression or death by 40% versus FASLODEX in advanced HR-positive breast cancer AstraZeneca